Regeneron's CIDEB siRNA cuts liver fat by up to 80% in early-stage trial

• Regeneron Pharmaceuticals reported its investigational CIDEB siRNA normalized liver fat in most MASLD patients in a first-in-human Phase 1/2 trial.
• A single dose improved liver injury markers, with effects sustained through 36 weeks, supporting potential twice-yearly dosing.
• Adverse event rates were generally similar to placebo; no participants discontinued the trial.
• Results were presented at AASLD’s 2026 Liver Meeting and published in The New England Journal of Medicine.
• Phase 2a, Phase 2b and Phase 3 trials are recruiting to assess longer-term safety and liver tissue outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081600PRIMZONEFULLFEED9872883) on November 08, 2026, and is solely responsible for the information contained therein.